- Pharmaceutical Research Development | AbbVie
AbbVie pharmaceuticals combines advanced science with expertise to make strides in drug and treatment discovery, making a remarkable impact on people's lives
- AbbVie - Wikipedia
AbbVie Inc is an American pharmaceutical company headquartered in North Chicago, Illinois
- AbbVie Inc. (ABBV) Stock Price, News, Quote History - Yahoo Finance
Find the latest AbbVie Inc (ABBV) stock quote, history, news and other vital information to help you with your stock trading and investing
- About AbbVie - Our Company | AbbVie
When we became our own company, AbbVie formed a new kind of enterprise—a biopharmaceutical company We blend the stability, global scale, resources and commercial capabilities of a pharmaceutical company with the focus and culture of a biotech
- AbbVie to Acquire Capstan Therapeutics, Further Strengthening . . .
AbbVie to Acquire Capstan Therapeutics, Further Strengthening Commitment to Transforming Patient Care in Immunology Capstan's lead asset, CPTX2309, is a targeted lipid nanoparticle (tLNP) that delivers an mRNA encoding an anti-CD19 chimeric antigen receptor (CAR) to CD8-expressing cytotoxic T cells in vivo, and is a potential first-in-class
- Investor Overview | AbbVie
AbbVie discovers, develops, and commercializes advanced therapies that have an impact on people's lives Today, our passionate AbbVie team has approximately ~50,000 employees working together to help patients around the world
- AbbVie cuts $1. 9bn+ deal with IGI for trispecific antibody
AbbVie has agreed to pay $700 million upfront for rights to a drug developed by Ichnos Glenmark Innovation (IGI) with potential as a treatment for blood cancers and autoimmune disorders
- Who We Are | AbbVie
AbbVie’s mission is to discover and deliver innovative medicines and solutions that address complex health issues and enhance people's lives
|